A US News and World Report article profiles a new test to determine the effectiveness of Alzheimer’s drugs developed by Cure Alzheimer’s Fund’s Dr. David Holtzman. The stable isotope-linked kinetics or SILK test quickly reveals whether medication is working to limit the harmful protein amyloid beta.

Click here to read full article